Arthritis Relief Plus receives positive results from a trial comparing Acteev® to a placebo
15 September 2008, Gold Coast, Australia: Today Arthritis Relief Plus Limited (ARP) announced the results of a double blind, placebo controlled randomized trial conducted by Oklahoma State University. (Read report)
The purpose of this study was to determine the effect of 2 concentrations of Acteev® and to compare them to placebo ointment on pain, stiffness and physical functioning in subjects with primary osteoarthritis of the knee.
Forty‐five male and female subjects ranging in age from 45 to 83 years with primary osteoarthritis of the knee applied the topical ointments 3 times a day for 6 weeks. Outcomes were measured using the pain, stiffness and function subscales of the WOMAC osteoarthritis index.
Patients using both concentrations of Acteev® experienced significant reductions in pain and stiffness, and improvement in daily activity while no significant changes in pain, stiffness, or daily activity were found for the placebo group. On the primary outcome of change in the WOMAC subscale, those using the higher and lower concentrations of Acteev® formula had a 65% and a 55% reduction in pain, a 53% and 42% reduction in stiffness, and a 64% and 61% improvement in daily activity respectively.
The results of the placebo study complements the positive results from a comparative study performed earlier through Oklahoma State University further validating the efficacy of Acteev®.
ARP Director, Persis Anderson said “Now that osteoarthritis is considered a metabolically active, reparative process amenable to treatment, products such as Acteev® have great potential to make a positive difference to the lives of millions of people. These results get us one step closer to making Acteev® available to those people”.